Inventiva (NASDAQ:IVA) Shares Gap Up – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $4.69, but opened at $4.87. Inventiva shares last traded at $4.7950, with a volume of 104,611 shares.

Analyst Upgrades and Downgrades

Several research firms have commented on IVA. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $16.56.

Inventiva Price Performance

The stock has a fifty day moving average price of $4.31 and a 200-day moving average price of $5.09.

Hedge Funds Weigh In On Inventiva

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP bought a new position in Inventiva in the first quarter worth about $1,111,000. Virtu Financial LLC purchased a new stake in shares of Inventiva during the fourth quarter valued at about $60,000. ADAR1 Capital Management LLC bought a new stake in shares of Inventiva in the 4th quarter valued at about $12,601,000. XTX Topco Ltd bought a new stake in shares of Inventiva in the 4th quarter valued at about $84,000. Finally, Yu Fan purchased a new position in shares of Inventiva in the 4th quarter worth approximately $6,975,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.